(Alliance News) - Summit Therapeutics PLC on Friday said its chief operating officer and chief medical officer David Roblin will resign in a week.
Shares in Summit were down 3.5% at 21.24 pence in London in midday trading.
Roblin was, in addiction to being COO and CMO, also president of research & development at antibiotics firm Summit.
Summit Chief Executive Glyn Edwards said: "David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our phase 3 clinical trials of ridinilazole for the treatment of C difficile infection.
"We are grateful to David for building a strong team that will continue to advance Summit's important work and wish him all the very best in his future endeavours."
It was not disclosed in Summit's release what Roblin's "future endeavours" will be.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
